Through logistic regression, we found T2 vs. T1 in primary tumor (total (N) = 280), the odds ratio in CPSF3 was 2.44 (95% CI: 1.46–4.14, p-Value = 0.0008); in tumor stage, II vs. I (total (N) = 262), the odds ratio in CPSF3 was 2.4 (95% CI: 1.40–4.15, p-value = 0.0015). This evidence concerns the gene CPSF3 and neoplasm.